WallStreetZenWallStreetZen

NASDAQ: CADL
Candel Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CADL

Based on 4 analysts offering 12 month price targets for Candel Therapeutics Inc

Min Forecast
$15.00+221.2%
Avg Forecast
$21.25+355.03%
Max Forecast
$25.00+435.33%

Should I buy or sell CADL stock?

Based on 4 analysts offering ratings for Candel Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CADL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CADL as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CADL stock forecasts and price targets.

CADL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-10-21
lockedlocked$00.00+00.00%2025-09-29

1 of 1

Forecast return on equity

Is CADL forecast to generate an efficient return?

Company
N/A
Industry
66.72%
Market
181.06%

Forecast return on assets

Is CADL forecast to generate an efficient return on assets?

Company
N/A
Industry
32.08%

CADL earnings per share forecast

What is CADL's earnings per share in the next 2 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$1.00
Avg 2 year Forecast
-$0.49

CADL revenue forecast

What is CADL's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$59.9M
Avg 3 year Forecast
$189.6M

CADL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CADL$4.67$21.25+355.03%Strong Buy
NERV$7.83$7.00-10.60%Hold
CLYM$7.03$16.17+129.97%Strong Buy
IMMX$10.00$16.33+63.33%Buy
FBRX$26.74$63.00+135.60%Strong Buy
View Top Biotech Stocks

Candel Therapeutics Stock Forecast FAQ

Is Candel Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CADL) stock is to Strong Buy CADL stock.

Out of 4 analysts, 3 (75%) are recommending CADL as a Strong Buy, 1 (25%) are recommending CADL as a Buy, 0 (0%) are recommending CADL as a Hold, 0 (0%) are recommending CADL as a Sell, and 0 (0%) are recommending CADL as a Strong Sell.

If you're new to stock investing, here's how to buy Candel Therapeutics stock.

What is CADL's earnings growth forecast for 2026-2027?

(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Candel Therapeutics's earnings in 2026 is -$38,182,000.On average, 8 Wall Street analysts forecast CADL's earnings for 2026 to be -$73,144,381, with the lowest CADL earnings forecast at -$105,087,366, and the highest CADL earnings forecast at -$37,685,544.

In 2027, CADL is forecast to generate -$36,022,839 in earnings, with the lowest earnings forecast at -$81,113,647 and the highest earnings forecast at $49,221,935.

What is CADL's revenue growth forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Candel Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast CADL's revenue for 2026 to be $0, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $0. On average, 8 Wall Street analysts forecast CADL's revenue for 2027 to be $4,383,975,075, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $12,720,793,812.

In 2028, CADL is forecast to generate $13,887,617,359 in revenue, with the lowest revenue forecast at $3,108,160,100 and the highest revenue forecast at $28,126,087,499.

What is CADL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CADL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.08%.

What is CADL's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CADL price target, the average CADL price target is $21.25, with the highest CADL stock price forecast at $25.00 and the lowest CADL stock price forecast at $15.00.

On average, Wall Street analysts predict that Candel Therapeutics's share price could reach $21.25 by Mar 13, 2027. The average Candel Therapeutics stock price prediction forecasts a potential upside of 355.03% from the current CADL share price of $4.67.

What is CADL's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CADL) Candel Therapeutics's current Earnings Per Share (EPS) is -$0.72. On average, analysts forecast that CADL's EPS will be -$1.00 for 2026, with the lowest EPS forecast at -$1.43, and the highest EPS forecast at -$0.51. In 2027, CADL's EPS is forecast to hit -$0.49 (min: -$1.11, max: $0.67).

What is CADL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CADL) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.